title: Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy.
abstract: It is desirable to quantify the distribution of the light fluence rate, the optical properties, the drug concentration, and the tissue oxygenation for photodynamic therapy (PDT) of prostate cancer. We have developed an integrated system to determine these quantities before and after PDT treatment using motorized probes. The optical properties (absorption (micro(a)), transport scattering (micro(s'), and effective attenuation (micro(eff)) coefficients) of cancerous human prostate were measured in-vivo using interstitial isotropic detectors. Measurements were made at 732 nm before and after motexafin lutetium (MLu) mediated PDT at different locations along each catheter. The light fluence rate distribution was also measured along the catheters during PDT. Diffuse absorption spectroscopy measurement using a white light source allows extrapolation of the distribution of oxygen saturation StO2, total blood volume ([Hb]t), and MLu concentration. The distribution of drug concentration was also studied using fluorescence from a single optical fiber, and was found to be in good agreement with the values determined by absorption spectroscopy. This study shows significant inter- and intra-prostatic variations in the tissue optical properties and MLu drug distribution, suggesting that a real-time dosimetry measurement and feedback system for monitoring these values during treatment should be considered in future PDT studies.
authors.affiliation: Department of Radiation Oncology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA.
authors.forename: Timothy C
authors.initials: TC
authors.lastname: Zhu
authors.forename: Jarod C
authors.initials: JC
authors.lastname: Finlay
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Hahn
mesh_terms: D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D006801:Humans; D008027:Light; D008297:Male; D008665:Metalloporphyrins / Q000627:therapeutic use*; D055095:Optics and Photonics; D010100:Oxygen / Q000378:metabolism*; D010778:Photochemotherapy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D013053:Spectrophotometry
chemical_list: D008665:Metalloporphyrins; C102825:motexafin lutetium; D010100:Oxygen